92196-29-7

Usage

Uses

Used in Pharmaceutical Industry:
(1-methylpiperidin-4-yl)(phenyl)methanol is used as a key intermediate for the synthesis of compounds with potential therapeutic applications in the treatment of various diseases and conditions. Its role in the development of new drugs makes it a valuable component in medicinal chemistry and drug discovery processes.
Used in Chemical Research and Development:
Beyond its applications in the pharmaceutical industry, (1-methylpiperidin-4-yl)(phenyl)methanol may also serve as a building block in the synthesis of other organic compounds, contributing to the advancement of chemical research and development in various fields. Its versatility as a chemical intermediate allows for its use in creating a wide range of products and materials.

Upstream product

• 50-00-0 formaldehyd 
• 38081-60-6 phenyl-piperidin-4-yl-methanol 
• 34285-40-0 4-benzoyl-1-methylpyridinium iodide 
• 60-29-7 diethyl ether 
• 92020-38-7 (4-bromo-1-methyl-[4]piperidyl)-phenyl ketone; hydrobromide 
• 92040-00-1 (1-methylpiperidin-4-yl)(phenyl)methanone 
• 2116-65-6 4-benzyl pyridine 
• 5570-77-4 4-chloro-1-methylpiperidine 
• 100-52-7 benzaldehyde 
• 25503-90-6 1-acetyl-piperidine-4-carboxylic acid 
• 59084-16-1 1-acetylpiperidine-4-carbonyl chloride 
• 37586-22-4 4-benzoylpiperidine 
• 5689-64-5 4-benzoyl-1-methyl-pyridinium; bromide 

Downstream Products

• 878162-21-1 4-(chloro(phenyl)methyl)-1-methylpiperidine 
• 6071-92-7 VUF 4589 

Relevant academic research and scientific papers

Grignard Reagents on a Tab: Direct Magnesium Insertion under Flow Conditions

An on-demand preparation of organomagnesium reagents is presented using a new flow protocol. The risks associated with the activation of magnesium are circumvented by a new on-column initiation procedure. Required amounts of solutions with a precise titration were obtained. Telescoped flow or batch reactions allow access to a diverse set of functional groups.

Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors

A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain.

HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of heterocyclic amides are disclosed of the general formula (I) where Z is N or CHNR2 and X is NR2, O, S, S=O or SO2. Among other definitions for R, R1, W and Y, the compounds of formula (1) are further characterized by at least one of W or Y being CR3Ar2 where Ar is an aromatic or heteroaromatic ring (for example, where W or Y is a benzhydryl moiety).

Urea derivatives as calcium channel blockers

Urea derivatives which comprise piperidine or piperazine rings and further substitution are effective in ameliorating conditions characterized by unwanted calcium ion channel activity.

Syntheses and Binding Studies of New [(Aryl)(aryloxy)methyl]piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters

In a wide search program toward new, efficient, and fast-acting antidepressant drugs, we have prepared series of new compounds having an (aryl)(aryloxy)methyl moiety linked directly or through a methylene chain to different substituted and unsubstituted cycles (isoquinoline, piperazine, piperidine, tetrahydropyran, or cyclopentane). These compounds have been evaluated for their affinities for serotonin (5-HT) transporter (SERT) and 5-HT1A and 5-HT2A receptors. Racemic mixtures of 4-[(aryl)(aryloxy)methyl]piperidine derivatives showed much higher affinity values for SERT than fluoxetine and resulted in lack of affinity for 5-HT 1A and 5-HT2A receptors. Some of these racemic mixtures were resolved to their enantiomers and tested for binding to norepinephrine (NE) transporter (NET), dopamine (DA) transporter (DAT), and α2 receptor. Several of these enantiomers [(-)-15b, (-)-15j, (-)-15t, (+)-15u] displayed a dual binding profile with affinities for SERT and NET with K i i = 1.9 and 13.5 nM, respectively), and further pharmacological characterization is in progress for its evaluation as a antidepressant.